GET DAILY SIGNALSWW International (WW) Delivers Q3 Profit Surprise Amid Ongoing Subscriber Shift
Key Takeaways
- Revenue came in at $152.9 million, down 11% year over year from $172.1 million, as a shrinking core subscription base continued to weigh on the top line.
- Net income turned positive at $15.1 million, marking the company's second consecutive profitable quarter since emerging from its 2025 financial reorganization.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, and share-based compensation) rose 21% to $51.7 million, with a 33.8% margin.
- Clinical subscription revenue jumped 48% to $38.0 million, now about 25% of total revenue versus 15% a year earlier.
- Core+ subscribers reached 546,000, up 16% year over year, while total behavioral subscribers fell 26% to roughly 2.1 million.
Why This Quarter Matters for WW International
WW International, the company behind the Weight Watchers brand, is navigating a pivotal transition from its legacy behavioral subscription model toward higher-value clinical weight-management services in the GLP-1 medication era. The third quarter offers investors a progress check on that pivot. The company emerged from Chapter 11 reorganization in mid-2025, sharply reduced its debt load, and installed a new chief executive, Stephen Bye, on October 1, 2026. This report matters because it tests whether management's cost discipline and clinical momentum can offset persistent declines in its core membership base, a dynamic central to the stock's longer-term story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
WW International reported third-quarter fiscal 2026 revenue of $152.9 million, an 11% decline from $172.1 million a year earlier and slightly below consensus estimates near $154 million. The decline was concentrated in behavioral subscription revenue, which fell 22% to $113.9 million, while clinical subscription revenue rose 48% to $38.0 million.
Profitability was the quarter's highlight. The company posted net income of $15.1 million, swinging from a $57.5 million net loss in the prior-year period. GAAP diluted earnings per share of $1.51 far exceeded the roughly $0.81 consensus estimate, though much of the swing reflected lower marketing and selling, general, and administrative expenses rather than revenue growth. Adjusted EBITDA climbed 21% to $51.7 million, with adjusted gross margin of 74.6%, the highest level of 2026.
Subscriber trends were mixed. Total end-of-period subscribers were about 2.3 million. Core+ subscribers reached 546,000, a fourth straight quarter of sequential growth, while clinical subscribers rose 40% year over year to 174,000 but declined sequentially from 197,000. Monthly subscription revenue per average subscriber (ARPU) increased 14% to $21.17. From what I see, the mixed subscriber picture remains the key tension in the story.
For fiscal 2026, management narrowed its full-year outlook to revenue of $625 million to $630 million and adjusted EBITDA of $110 million to $115 million, while raising adjusted gross margin guidance to approximately 74%.
Market Reaction and Investor Sentiment
Shares of WW traded higher following the release, as investors weighed a sizable bottom-line beat and improving margins against the continued contraction in the subscriber base. The earnings-per-share surprise of roughly 86% above consensus reflected disciplined cost management rather than sales momentum, and analysts noted that the profit swing was driven substantially by reduced marketing and overhead spending. Sentiment remains divided: bulls point to the accelerating clinical revenue mix and Core+ growth, while bears highlight the 26% decline in behavioral subscribers and the sequential dip in clinical members as evidence that the company has yet to stabilize its overall customer base.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should watch whether WW International can translate its improving profitability into durable revenue stability. Management signaled that marketing spend will step up modestly in the fourth quarter ahead of the seasonally important peak period, which could pressure near-term margins even as it aims to support subscriber acquisition.
The clinical business remains the central growth narrative. Management expects further moderate sequential declines in clinical subscribers during the fourth quarter as a group of 12-month plans rolls off, but sees meaningful opportunity to expand awareness of its Med+ offering through a more diversified marketing approach. New partnerships, including Google Health, Sam's Club, and Lilly Direct, were described as too early to measure.
Balance-sheet progress is another positive to monitor. Total debt has fallen more than 70% since reorganization, to about $423.6 million, and cash rose to $126.4 million. Continued operating cash flow generation and disciplined spending will be key to sustaining that trajectory.
Finally, the leadership transition under new CEO Stephen Bye adds an element of strategic uncertainty. His early focus on member experience, product improvements, and the integration of behavioral and clinical offerings may reshape priorities in the quarters ahead. Investors will be watching for clearer signals on how the company intends to reverse core subscriber declines while preserving the margin gains achieved this year.
Exploring Tickeron’s AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Screener provide a practical way to cross-check earnings data against broader market patterns and peer comparisons. I often turn to it when evaluating names in transition, as it helps surface relevant technical and fundamental signals without manual effort. This kind of resource has become part of my regular workflow for staying on top of evolving stories like the one at WW.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for WW turns negative, indicating new downward trend
WW saw its Momentum Indicator move below the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 85 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for WW turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
WW moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for WW crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for WW entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +9.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where WW advanced for three days, in 212 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
WW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. WW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.461) is normal, around the industry mean (204.059). P/E Ratio (0.939) is within average values for comparable stocks, (18.581). Projected Growth (PEG Ratio) (5.307) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (0.167) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of weight management services
Industry HospitalNursingManagement
Advertisement